The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Elias Jabbour
Steering Committee Member
Elias Jabbour is a professor of medicine in the Department of Leukemia, Division of Cancer Medicine, at the MD Anderson Cancer Center, Houston, US. He received education and training in the US, France, and Lebanon in the fields of hematology, hematology-oncology, and clinical carcinology. He has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others, including the hyper CVAD-ofatumumab regimen in ALL; clofarabine in myeloid malignancies; hypomethylating agents in acute myeloid leukemia (AML) and myelodysplastic syndromes; tyrosine kinase therapy in chronic myeloid leukemia; and triple therapy in AML.
Filter by content: